All News

Medical director of the NFID William Schaffner, MD, discusses the research behind the FDA's decision to approve the first-ever RSV vaccine.

Efficacy of the daily pill met the standard now established by the once-weekly injection of 15% loss of baseline bodyweight in adults with overweight or obesity, says Novo Nordisk.

Your daily dose of clinical news you may have missed.

A nationally recognized obesity expert discusses mental health in women with obesity.

The findings contradict published clinical guidelines that warn against use of estrogen-containing birth control by women who have migraine with aura.

Findings of the BOREAS trial of patients with COPD and type 2 inflammation make dupilumab the first biologic to significantly reduce exacerbations by 30% vs placebo.

Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.

Your daily dose of clinical news you may have missed.

Statin therapy initiated within 1 year of diagnosis of atrial fibrillation reduced the risk of ischemic stroke or systemic embolism by nearly 20%.

The Pfizer vaccine RSVpreF administered to pregnant people was judged by the advisory committee to be effective at preventing RSV in infants from birth to 6 months.

Kelly Moore, MD, MPH, says the public health community is relieved by the FDA's approval and excited at "the chance to finally do something about the disease."

Your daily dose of clinical news you may have missed.

“Patients with COPD who have AMI are less aggressively treated than those without COPD," leading to higher in-hospital mortality and long-term mortality,” wrote authors.

In a new guideline, the WHO recommends against the use of nonsugar sweeteners to control body weight or reduce the risk of noncommunicable diseases.

Patients with rheumatoid arthritis and fibromyalgia were at the greatest risk of transitioning to long-term opioid use 1 year after a first prescription, a new study found.

The label expansion is based on findings from the pivotal phase 3 DELIVER trial in which dapagliflozin reduced the composite CV/HF endpoint in HF patients with HFmrEF or HFpEF.

Your daily dose of clinical news you may have missed.

AACE 2023. Deaths among persons with diabetes in the US related to vascular complications increased from 2001 to 2020, primarily driven by renal complications.